Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million individual investors worldwide.
Afya (NasdaqGS:AFYA) has drawn attention after recent share price moves, with the stock up about 1.9% over the past day but showing negative returns over the past month and past 3 months.
The Brazil based medical education group reports annual revenue of R$3,633.28 and net income of R$729.426. It operates across undergraduate programs, continuing education, and a range of digital health services for medical professionals and students.
See our latest analysis for Afya.
At a share price of $13.76, Afya’s recent 1 day share price gain contrasts with a 7.96% year to date share price decline and a 22.69% 1 year total shareholder return loss. This suggests momentum has been fading despite a 31.13% 3 year total shareholder return gain.
If Afya’s moves have you reassessing your watchlist, this could be a useful moment to broaden your search with our 18 top founder-led companies as potential long term compounders.
With Afya trading at $13.76 alongside an indicated intrinsic discount of about 54% and a 24% gap to analyst targets, you have to ask whether the market is overlooking value or already pricing in the growth story.
Afya’s most followed narrative, according to NateF, points to a fair value of about $14.86 versus the $13.76 last close. This frames a modest discount and a fairly supportive earnings profile.
Afya’s growth prospects are underpinned by strong demand for healthcare professionals, regulatory tailwinds in medical education, and opportunities in digital transformation. However, risks such as economic volatility, regulatory challenges, and increasing competition could impact its performance.
Curious what sits behind that fair value gap? The narrative leans heavily on compounding earnings, steady revenue expansion, and margins that assume Afya keeps scaling its medical education niche and digital health tools.
Result: Fair Value of $14.86 (UNDERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, shifting regulations around tuition or medical seat approvals, along with any renewed economic pressure on Brazilian students, could quickly weaken that modest undervaluation argument.
Find out about the key risks to this Afya narrative.
All this leaves the sentiment mixed, so it is worth moving quickly and checking the data yourself to decide where you stand, starting with 5 key rewards.